Literature DB >> 27908840

Prescription Opioid Taper Support for Outpatients With Chronic Pain: A Randomized Controlled Trial.

Mark D Sullivan1, Judith A Turner2, Cory DiLodovico2, Angela D'Appollonio2, Kari Stephens2, Ya-Fen Chan2.   

Abstract

Patients receiving long-term opioid therapy for chronic pain and interested in tapering their opioid dose were randomly assigned to a 22-week taper support intervention (psychiatric consultation, opioid dose tapering, and 18 weekly meetings with a physician assistant to explore motivation for tapering and learn pain self-management skills) or usual care (N = 35). Assessments were conducted at baseline and 22 and 34 weeks after randomization. Using an intention to treat approach, we constructed linear regression models to compare groups at each follow-up. At 22 weeks, adjusted mean daily morphine-equivalent opioid dose in the past week (primary outcome) was lower in the taper support group, but this difference was not statistically significant (adjusted mean difference = -42.9 mg; 95% confidence interval, -92.42 to 6.62; P = .09). Pain severity ratings (0-10 numeric rating scale) decreased in both groups at 22 weeks, with no significant difference between groups (adjusted mean difference = -.68; 95% confidence interval, -2.01 to .64; P = .30). The taper support group improved significantly more than the usual care group in self-reported pain interference, pain self-efficacy, and prescription opioid problems at 22 weeks (all P-values < .05). This taper support intervention is feasible and shows promise in reducing opioid dose while not increasing pain severity or interference. PERSPECTIVE: In a pilot randomized trial comparing a prescription opioid taper support intervention to usual care, lower opioid doses and pain severity ratings were observed at 22 weeks in both groups. The groups did not differ significantly at 22 weeks in opioid dose or pain severity, but the taper support group improved significantly more in pain interference, pain self-efficacy, and perceived opioid problems. These results support the feasibility and promise of this opioid taper support intervention.
Copyright © 2016 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic opioid therapy; opioid dose taper; pain intensity; pain interference; pain self-management

Mesh:

Substances:

Year:  2016        PMID: 27908840      PMCID: PMC5337146          DOI: 10.1016/j.jpain.2016.11.003

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  31 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  Addressing the Opioid Epidemic.

Authors:  Lewis S Nelson; David N Juurlink; Jeanmarie Perrone
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

3.  A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission.

Authors:  Cynthia O Townsend; Jennifer L Kerkvliet; Barbara K Bruce; Jeffrey D Rome; Michael W Hooten; Connie A Luedtke; John E Hodgson
Journal:  Pain       Date:  2008-09-19       Impact factor: 6.961

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Somatic complaints in primary care: further examining the validity of the Patient Health Questionnaire (PHQ-15).

Authors:  Alejandro Interian; Lesley A Allen; Michael A Gara; Javier I Escobar; Angélica M Díaz-Martínez
Journal:  Psychosomatics       Date:  2006 Sep-Oct       Impact factor: 2.386

6.  Prescription practices involving opioid analgesics among Americans with Medicaid, 2010.

Authors:  Karin A Mack; Kun Zhang; Leonard Paulozzi; Christopher Jones
Journal:  J Health Care Poor Underserved       Date:  2015-02

7.  Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population.

Authors:  Bernd Löwe; Oliver Decker; Stefanie Müller; Elmar Brähler; Dieter Schellberg; Wolfgang Herzog; Philipp Yorck Herzberg
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

Review 8.  Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research.

Authors:  Dawn M Ehde; Tiara M Dillworth; Judith A Turner
Journal:  Am Psychol       Date:  2014 Feb-Mar

Review 9.  Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature.

Authors:  Silvia S Martins; Laura Sampson; Magdalena Cerdá; Sandro Galea
Journal:  Am J Public Health       Date:  2015-11       Impact factor: 9.308

10.  Validation of the Brief Pain Inventory for chronic nonmalignant pain.

Authors:  Gabriel Tan; Mark P Jensen; John I Thornby; Bilal F Shanti
Journal:  J Pain       Date:  2004-03       Impact factor: 5.820

View more
  40 in total

1.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

2.  Optimizing pain treatment interventions (OPTI): A pilot randomized controlled trial of collaborative care to improve chronic pain management and opioid safety-Rationale, methods, and lessons learned.

Authors:  Karen H Seal; Brian Borsari; Jennifer Tighe; Beth E Cohen; Kevin Delucchi; Benjamin J Morasco; Yongmei Li; Emily Sachs; Linda Abadjian; Erin C Watson; Jennifer K Manuel; Lea Vella; Jodie Trafton; Amanda Midboe
Journal:  Contemp Clin Trials       Date:  2018-12-17       Impact factor: 2.226

3.  Opioid Taper Is Associated with Subsequent Termination of Care: a Retrospective Cohort Study.

Authors:  Hector R Perez; Michele Buonora; Chinazo O Cunningham; Moonseong Heo; Joanna L Starrels
Journal:  J Gen Intern Med       Date:  2019-08-19       Impact factor: 5.128

4.  Analgesic reduction during an interdisciplinary pain management programme: treatment effects and processes of change.

Authors:  Beth J Guildford; Aisling Daly-Eichenhardt; Bethany Hill; Karen Sanderson; Lance M McCracken
Journal:  Br J Pain       Date:  2017-10-02

Review 5.  Prescribing wellness: comprehensive pain management outside specialist services.

Authors:  Simon Holliday; Chris Hayes; Lester Jones; Jill Gordon; Newman Harris; Michael Nicholas
Journal:  Aust Prescr       Date:  2018-05-15

Review 6.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

7.  Effect of cognitive behavioural therapy on sleep and opioid medication use in adults with fibromyalgia and insomnia.

Authors:  Christina S McCrae; Ashley F Curtis; Mary Beth Miller; Neetu Nair; Himangshu Rathinakumar; Mattina Davenport; Jasmine R Berry; Kevin McGovney; Roland Staud; Richard Berry; Michael Robinson
Journal:  J Sleep Res       Date:  2020-03-03       Impact factor: 3.981

8.  "I'm Not Gonna Pull the Rug out From Under You": Patient-Provider Communication About Opioid Tapering.

Authors:  Marianne S Matthias; Nicole L Johnson; Cleveland G Shields; Matthew J Bair; Palmer MacKie; Monica Huffman; Stewart C Alexander
Journal:  J Pain       Date:  2017-07-08       Impact factor: 5.820

9.  Race and Gender Are Associated with Opioid Dose Reduction Among Patients on Chronic Opioid Therapy.

Authors:  Michele Buonora; Hector R Perez; Moonseong Heo; Chinazo O Cunningham; Joanna L Starrels
Journal:  Pain Med       Date:  2019-08-01       Impact factor: 3.750

10.  Medical Record Documentation About Opioid Tapering: Examining Benefit-to-Harm Framework and Patient Engagement.

Authors:  Michele Buonora; Hector R Perez; Jordan Stumph; Robert Allen; Shadi Nahvi; Chinazo O Cunningham; Jessica S Merlin; Joanna L Starrels
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.